Alpine Immune Sciences to Present at Two Upcoming Investor Conferences in November

Alpine Immune Sciences, Inc. ALPN, a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced the company will present at two upcoming investor conferences in November.

Stifel 2017 Healthcare Conference

Tuesday, November 14, 2017, at 3:30 p.m. Eastern Time in New York.

29^th Annual Piper Jaffray Healthcare Conference

Wednesday, November 29, 2017, at 10:50 a.m. Eastern Time in New York.

A live webcast of each presentation will be available online by visiting the investor relations page of the Company's website, at https://ir.alpineimmunesciences.com/events. An archive of each webcast will be available on the Company's website for 30 days.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is focused on developing novel protein-based immunotherapies using its proprietary Variant Ig Domain (vIgD) platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine's vIgDs are developed using a process known as directed evolution, which produces proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to cancer, autoimmune, and inflammatory diseases. Alpine has also developed Transmembrane Immunomodulatory Protein (TIP) technology, based on the vIgD platform, to potentially enhance engineered cellular therapies. For more information visit www.alpineimmunesciences.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171101006252/en/